2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.01. Changes in PD-L1 Expression and Tumor Mutational Burden Between Paired Samples and Relationship to Immune Checkpoint Inhibitor Outcomes in Patients with Non-Small Cell Lung Cancer

P1.01. Changes in PD-L1 Expression and Tumor Mutational Burden Between Paired Samples and Relationship to Immune Checkpoint Inhibitor Outcomes in Patients with Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study explores the variations in programmed cell death receptor ligand 1 (PD-L1) tumor proportion score (TPS) and tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC) and the impact on the outcomes of patients receiving immune checkpoint inhibitors (ICI). The researchers collected clinicopathologic and genomic data from patients with NSCLC and multiple tumor samples tested for PD-L1 TPS or TMB. They found that while there was generally high concordance between sample pairs in PD-L1 and TMB, there were variations with potential clinical implications. Major changes in PD-L1 TPS were associated with acquired genomic alterations. The study suggests that the most recent PD-L1 assessment before immunotherapy administration may be a more accurate predictor of response compared to older samples. The researchers also analyzed the association of intervening immunotherapy with PD-L1 and TMB variations and found that patients who received immunotherapy had significant decreases in PD-L1 TPS and TMB compared to those who received other systemic treatments or no treatment. Finally, the study examined the outcomes of patients based on the most recent PD-L1 TPS prior to immunotherapy and found that patients with a TPS of 1% had longer progression-free survival and overall survival compared to those with a TPS of 1%. Overall, this study provides insights into the variations of PD-L1 and TMB in NSCLC and their impact on immunotherapy outcomes, emphasizing the importance of considering the timing and accuracy of these biomarker assessments.

Asset Subtitle

Alessandro Di Federico, Dana-Farber Cancer Institute, United States

Meta Tag

Speaker Alessandro Di Federico, Dana-Farber Cancer Institute, United States

Topic Poster Listing

Keywords

PD-L1

TPS

TMB

NSCLC

immune checkpoint inhibitors

genomic data

acquired genomic alterations

immunotherapy administration

progression-free survival

overall survival